Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 19/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578700 | 1.00 | CXCR3 (0.53) | CXCR3KCNH2HRH3 | |
| SCHEMBL1888477 | 0.90 | CXCR3 (0.56) | CXCR3KCNH2HRH3 | |
| SCHEMBL5577398 | 0.90 | CXCR3 (0.56) | CXCR3KCNH2HRH3 | |
| SCHEMBL1894541 | 0.89 | CXCR3 (0.58) | CXCR3 | |
| SCHEMBL12659747 | 0.82 | HRH3 (0.54) | CXCR3KCNH2HRH3 | |
| SCHEMBL1895439 | 0.79 | PIK3CD (0.48) | CXCR3KCNH2HRH3 | |
| SCHEMBL1895441 | 0.79 | PIK3CD (0.48) | CXCR3KCNH2HRH3 | |
| SCHEMBL12659732 | 0.78 | PIK3CD (0.48) | CXCR3KCNH2HRH3 | |
| SCHEMBL5578377 | 0.77 | KCNH2 (0.49) | CXCR3KCNH2HRH3 | |
| SCHEMBL12672676 | 0.76 | PIK3CD (0.50) | CXCR3KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939538-B2 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20060069099-A1 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN SF, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069099-A1 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | MSR1, TNF, HLA-DRB1 | CXCR3 85/4885KCNH2 3460/4885HRH3 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.